B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function

BMC Nephrology

Farooq Ghani²  Hira Shahzad³  Iqbal Azam⁴  Imran Siddiqui²  Javed Tai¹  Waqar Kashif¹  Lena Jafri² 

[1] Department of Medicine, Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan;Department of Pathology & Microbiology, Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan;Medical College Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan;Department of Community Health Services, Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan

关键词: Kidney;    NT-proBNP;    Heart failure;    B-Type natriuretic peptide;   

Others  :  1082922
DOI  :  10.1186/1471-2369-14-117

 received in 2012-11-02, accepted in 2013-05-15,  发布年份 2013

【 摘 要 】

Background

The effect of impaired kidney function on B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) is vague. This study was performed to examine the effect of kidney dysfunction on the afore-mentioned markers and determine appropriate cutoffs for systolic heart failure (SHF).

Methods

In this cross sectional study adults with estimated glomerular filtration rate (eGFR) <60 ml/min for ≥3 months were identified in consulting clinics from June 2009 to March 2010. SHF was defined as documented by a cardiologist with ejection fraction of < 40% and assessed by New York Heart Association classification (NYHA). Plasma was assayed for creatinine (Cr), BNP and NT-proBNP.

Results

A total of 190 subjects were enrolled in the study, 95 with and 95 without SHF. The mean age of patients was 58 (±15) years, 67.4% being males. Mean BNP levels showed a 2.5 fold and 1.5 fold increase from chronic kidney disease (CKD) stage 3 to stage 5 in patients with and without SHF respectively. NT-proBNP levels in non-heart failure group were 3 fold higher in CKD stage 5 compared to stage 3. Mean NT-proBNP levels were 4 fold higher in CKD stage 5 compared to stage 3 in patients with SHF. Optimal BNP and NT-proBNP cutoffs of SHF diagnosis for the entire CKD group were 300 pg/ml and 4502 pg/ml respectively.

Conclusion

BNP and NT-proBNP were elevated in kidney dysfunction even in the absence of SHF; however the magnitude of increase in NT-proBNP was greater than that of BNP. BNP and NT-proBNP can be useful in diagnosing SHF, nonetheless, by using higher cutoffs stratified according to kidney dysfunction. NT-proBNP appears to predict heart failure better than BNP.

【 授权许可】

   
2013 Jafri et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003, 41(1):1-12.
• [2]Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC: Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003, 14:S131-S138.
• [3]Zuo L, Ma YC, Zhou YH, Wang M, Xu GB, Wang HY: Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 2005, 45(3):463-472.
• [4]Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
• [5]Jafar TH, Schmid CH, Levey AS: Serum creatinine as marker of kidney function in South Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol 2005, 16(5):1413-1419.
• [6]King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9):1414-1431.
• [7]Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG, Babilonia NA, Rahman AR, Sheikh S, Tomlinson B, Sarraf-Zadigan N: Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000, 14:749-763.
• [8]Hameed K, Kadir M, Gibson T, Sultana S, Fatima Z, Syed A: The frequency of known diabetes, hypertension and ischaemic heart disease in affluent and poor urban populations of Karachi, Pakistan. Diabet Med 1995, 12(6):500-503.
• [9]Curtis BM, Parfrey PS: Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiol Clin 2005, 23(3):275-284.
• [10]Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N: Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003, 42:1793-1800.
• [11]Shapiro BP, Chen HH, Burnett JC Jr, Redfield MM: Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc 2003, 78(4):481-486.
• [12]McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AHB, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS: B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003, 41(3):571-579.
• [13]Dhar S, Pressman GS, Subramanian S, Kaul S, Gollamudi S, Bloom EJ, Figueredo VM: Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence. Postgrad Med J 2009, 85:299-302.
• [14]Clerico A, Giannoni A, Vittorini S, Passino C: Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 301(1):H12-H20.
• [15]Daniels LB, Maisel AS: Natriuretic peptides. J Am Coll Cardiol 2007, 50(25):2357-2368.
• [16]Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC Jr, Ikeda Y: Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem 57:864-873.
• [17]Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, Masuda I, Nakanishi K, Yoshimasa T, Hashimoto Y: Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995, 92:1558-1564.
• [18]Soleilhac JM, Lucas E, Beaumont A, Turcaud S, Michel JB, Ficheux D, Fournie-Zaluski MC, Roques BP: A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol 1992, 41:609-614.
• [19]Vanderheyden M, Bartunek J, Goethals M: Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004, 6(3):261-268.
• [20]Chen HH, Burnett JC Jr: The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999, 111(5):406-416.
• [21]McCullough PA, Omland T, Maisel AS: B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003, 4(2):72-80.
• [22]Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339(5):321-328.
• [23]Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16(1):31-41.
• [24] : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266.
• [25]Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29(19):2388-2442.
• [26]Maffei S, Del Ry S, Prontera C, Clerico A: Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Lond) 2001, 101(5):447-453.
• [27]Karjalainen AH, Ruskoaho H, Vuolteenaho O, Heikkinen JE, Backstrom AC, Savolainen MJ, Kesaniemi YA: Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. Maturitas 2004, 47:201-208.
• [28]Luchner A, Hengstenberg C, Lowel H, Buchner S, Schunkert H, Riegger GA, Holmer S: NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Card Fail 2005, 11:S21-27.
• [29]deFilippi CR, Seliger SL, Maynard S, Christenson RH: Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007, 53(8):1511-1519.
• [30]Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr: Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006, 47:91-97.
• [31]Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S: Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005, 46(1):118-123.
• [32]Felker GM, Petersen JW, Mark DB: Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006, 175(6):611-617.
• [33]National Clinical Guideline Centre (UK): Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update [Internet]. London: Royal College of Physicians (UK); 2010. (NICE Clinical Guidelines, No. 108.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK65340/ webcite
• [34]Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
• [35]McCullough PA, Kuncheria J, Mathur VS: Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med. 2003, 4(Suppl 7):S3-S12.
• [36]Yang JW, Kim MS, Kim JS, Yoo JM, Han ST, Kim BR, Kim YD, Choi SO, Han BG: Relationship between serum brain natriuretic peptide and heart function in patients with chronic kidney disease. Korean J Intern Med 2008, 23:191-200.
• [37]McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002, 106:416-422.
• [38]Ouanes I, Jalloul F, Ayed S, Dachraoui F, Ouanes-Besbes L, Fekih Hassen M, Elatrous S, Abroug F: N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Respirology 17:660-666.
• [39]Zhao XY, Yang YJ, Zhang J, Kang LM, Wei BQ, Gao XJ, Lu R, Zhang CL: Association of plasma amino-terminal pro-A-, B- and C-type natriuretic peptide levels with NYHA grade and echocardiographic derived parameters of cardiac function in heart failure patients. Zhonghua Xin Xue Guan Bing Za Zhi 2009, 37:486-490.
• [40]Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31:202-208.
• [41]Mishra RK, Li Y, Ricardo AC, Yang W, Keane M, Cuevas M, Christenson R, deFilippi C, Chen J, He J, Kallem RR, Raj DS, Schelling JR, Wright J, Go AS, Shlipak MG: Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). Am J Cardiol 111:432-438.
• [42]Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997, 96:509-516.
• [43]Goetze JP, Kastrup J, Rehfeld JF: The paradox of increased natriuretic hormones in congestive heart failure patients: does the endocrine heart also fail in heart failure? Eur Heart J 2003, 24(16):1471-1472.
• [44]Goetze JP: Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004, 50(9):1503-1510.
• [45]Chen HH: Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol. 2007, 49(10):1089-1091.
• [46]Clerico A, Zaninotto M, Prontera C, Giovannini S, Ndreu R, Franzini M, Zucchelli GC, Plebani M: State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study. Clin Chim Acta 414:112-119.